ALNY News - Candlesense

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension ...

What is the anticipated impact of the new data on Alnylam's long‑term revenue growth and profitability outlook? How might the new data influence Alnylam's cash burn rate and future financing needs? Are there any disclosed safety or efficacy concerns in the new data that could affect investor sentiment?

Clinical trials

15 days ago

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canacc...

Will the webcast provide insight into cost‑structure or margin improvements for upcoming product launches? How does this event compare to prior Alnylam investor conferences in terms of market impact? What is the market's likely reaction if Alnylam announces setbacks or positive milestones in the presentation?

Investor event

21 days ago

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointe...

Appointments

2 months ago